Agency launches DTP modular suite

Share this article:
Direct marketing agency Targetbase has launched XACT Direct-to-Patient, a proprietary modular suite delivering customer relationship management by way of marketing solutions for the healthcare industry.

“DTP is driven by gathered intelligence about patients—using the web as a listening post to attune communication strategies,” said Brian Kaiser, vice president at Targetbase. In order to communicate effectively, rapid and relevant response to the needs of patients is essential. That requires a seamless integration of analytics, creative and technology competencies, he explained.

“Companies have to communicate at relationship speed: the speed by which a patient engages, not two weeks later,” said Kaiser. “Patient needs aren't fixed. Brands have to act quickly, before the information expires. They have to evolve with patients' needs.” The XACT platform addresses three primary solutions for clients: prospecting patient audiences and building databases; promoting patient compliance, persistence and loyalty; and using lifestyle management to fuel new product launches and line extensions for brand franchises.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?